AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00867464 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00867464 — intervention group
Intervention type: OTHER
Intervention: Long-term Follow-up
Description: Undergo extended follow-up
Study NCT00867464 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04294199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Range of MOtion
Description: Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
Study NCT04294199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Range of MOtion
Description: Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
Study NCT02658669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia
Description: Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
Study NCT02448329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
Study NCT02448329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study NCT03349151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding
Description: Feeding on postoperative 2nd hour on return to the ward
Study NCT03349151 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: On- Demand feeding
Description: Feeding whenever the patient asks for on return to the ward
Study NCT03444896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
Study NCT03444896 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture group
Description: Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
Study NCT00371098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination: Influvac (SolvayPharma)
Study NCT00371098 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo influenza vaccine
Study NCT02084199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 10 days
Study NCT02658669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
Study NCT03970538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimFlow System
Description: Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
Study NCT03613025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sampling of non-invasive and/or non-targeted respiratory tract specimens
Description: Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 2
Description: concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 3
Description: concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 4
Description: concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 5
Description: concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 6
Description: concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03099577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 7
Description: concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
Study NCT03075748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAAA Debranching Stent Graft System
Description: The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
Study NCT02446444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02446444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional NSAA
Study NCT03997383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
Study NCT03997383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran will be administered by intravenous (IV) infusion.
Study NCT03997383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patisiran
Description: Patisiran will be administered by intravenous (IV) infusion.
Study NCT02446444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHA
Study NCT02446444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHA
Study NCT02446444 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Study NCT02446444 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Study NCT01733121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 25 mg capsule
Study NCT01733121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg capsule
Study NCT01733121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03128619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo biopsy
Study NCT03128619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT03128619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03128619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03128619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03128619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03791762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne Gold
Description: WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting.
Study NCT03791762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Description: Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting.
Study NCT03791762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Description: ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
Study NCT02521792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
Study NCT04237545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 short and restoration (prosthesis)
Description: A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
Study NCT04237545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T3 standard length and restoration (prosthesis)
Description: A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
Study NCT04718480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po placebo tablets
Study NCT04718480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: po fluvoxamine tablets
Study NCT00635544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
Study NCT00635544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
Study NCT00426764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
Study NCT04346576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics prevent health problems in children
Description: A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
Study NCT02894814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-Stop Dispensing
Description: Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
Study NCT02894814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-Stop Dispensing and focused dialogue
Description: Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
Study NCT04010292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education card
Description: Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
Study NCT01188668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Period 1-Aripiprazole 5mg on study day 1.
Study NCT01188668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole + desvenlafaxine succinate sustained release
Description: Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
Study NCT01585246 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saw Palmetto
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
Study NCT01585246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saw Palmetto
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
Study NCT04439331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib Hydrochloride
Description: Given PO
Study NCT03388606 — intervention group
Intervention type: BEHAVIORAL
Intervention: Growth Mindset
Description: 30 Minute interactive video
Study NCT01585246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil soft gel
Description: placebo (soybean oil soft gel)
Study NCT04552132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multisonic vs Sonic activation of irrigants
Description: Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
Study NCT00750841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: 45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
Study NCT02240238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
Study NCT02240238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
Study NCT03819465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
Study NCT04552132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multisonic vs Sonic activation of irrigants
Description: Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
Study NCT00920959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 100mcg
Description: Once-daily dosing
Study NCT00920959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC 100/50mcg
Description: Once-daily dosing
Study NCT00920959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily dosing
Study NCT02600923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
Study NCT02600923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
Study NCT02931786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol, midazolam and atropine administration via intravenous cannula.
Study NCT02931786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine propofol mixture
Description: Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
Study NCT04262063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell play do technique
Description: it apply the concept of learning by doing .children will enjoy playing with customized dental models
Study NCT04262063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell show do
Description: Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
Study NCT01843803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient inventory
Description: Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
Study NCT01843803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: attention control
Description: Patients will view a brief healthy living video on an iPad
Study NCT03758157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: welloStationX
Description: welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
Study NCT03758157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SureTemp
Description: SureTemp is an oral thermometer to measure human body skin temperature.
Study NCT00086450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft
Description: For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
Study NCT00086450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery.